- Home
- TRI vs TAK Comparison
TRI vs TAK Comparison
Compare TRI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRI | TAK |
|---|---|---|
| Founded | 1851 | 1781 |
| Country | Canada | Japan |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 55.5B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TRI | TAK |
|---|---|---|
| Price | $105.71 | $18.18 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $154.58 | N/A |
| AVG Volume (30 Days) | 2.3M | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | 2.62% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.90 | $0.16 |
| Revenue Next Year | $7.89 | $1.22 |
| P/E Ratio | ★ $25.72 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.28 | $12.99 |
| 52 Week High | $180.00 | $18.90 |
Technical Indicators
Market Signals| Indicator | TRI | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 64.04 |
| Support Level | $81.19 | $17.65 |
| Resistance Level | $113.40 | $18.74 |
| Average True Range (ATR) | 5.45 | 0.22 |
| MACD | -0.23 | 0.07 |
| Stochastic Oscillator | 53.49 | 84.74 |
Price Performance
Historical ComparisonAbout TRI Thomson Reuters Corp
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.